Objective To study the expression of p16 and Rb gene in primary gallbladder carcinoma (PGC). MethodsFiftysix cases of PGC and 26 of gallbladder benign lesions were observed by immunohistochemistry (SP). ResultsThe positive rates of p16 and Rb protein in PGC were 46.3% and 71.4% respectively. No association of Rb expression with histological grade, histological type, invasion, metastasis and prognosis was found. There were close correlation between p16 expression and invasion, metastasis as well as prognosis. The inverse correlation of p16 and Rb gene expression in PGC was confirmed. Conclusion The loss of p16 or Rb gene protein is an important molecular event in PGC,and closely related to the block in the negative regulatory pathway of all cell cycle. The detection of p16 protein may be useful in evaluating biological characteristics and prognosis in PGC.
【摘要】 目的 分析成都市近年一線抗結核藥的耐藥狀況，為耐藥結核病預防控制提供依據。 方法 對成都市2007年1月-2009年12月就診的結核患者，臨床分離株培養鑒定為結核分枝桿菌的菌株采用絕對濃度法進行一線抗結核藥:鏈霉素（SM）、異煙肼（INH）、利福平（RF）、乙胺丁醇（EMB）耐藥性檢測，分析結核分枝桿菌的耐藥情況。 結果 1 235例結核患者中，總耐藥率和總耐多藥率分別為28.83%、14.01%，初始耐藥率和獲得性耐藥率分別為12.82%、61.27%。近3年耐多藥率有下降趨勢，但獲得性耐藥率呈逐年上升趨勢。 結論 成都市結核耐藥狀況仍然比較嚴重，進一步加強耐藥結核的監測和控制非常重要。【Abstract】 Objective To analyze the drug resistant treating mycobacterium tuberculosis (MTB) in Chengdu in recent three years, and to provide the evidence for tuberculosis controlling. Methods The patients with MTB diagnosed from January 2007 to December 2009 in Chengdu were enrolled. Absolute concentration method was used to test the drug-resistance of streptomycin (SM), isoniazide (INH), rifampicin (RFP), and ethambutol (EMB). Results The total rate of drug resistance and multi-drug resistance were 28.83% and 14.01% respectively. The rates of initial drug resistance and the acquired drug resistance were 12.88% and 61.27% respectively. Multi-drug resistance rate showed a downward trend, but the rate of acquired drug resistance increased gradually. Conclusion The situation of drug resistance of tuberculosis in Chengdu is still serious, and it′s very important to further monitor and control the drug resistance treating tuberculosis.